x min read

BPS initiates coverage on Bio Matrix Scientific Group Inc (OTCMKTS:BMSN)

BPS initiates coverage on Bio Matrix Scientific Group Inc (OTCMKTS:BMSN)
Written by
Aaron Smith
Published on
October 30, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

On 22nd October’14, BrilliantPennyStocks.com initiated coverage on BMSN. The stock declined by 8.33% since the coverage was initiated.

Bio Matrix Scientific Group Inc (OTCMKTS:BMSN) majority owned subsidiary Regen BioPharma Inc. (OTCBB:RGBP) announced on 28th October that its Chief Scientific Officer Dr. Thomas Ichim is examining how it can leverage its patented Immuno therapeutic Treatment technique for treating Ebola in tandem with other investigative therapies. The treatment being proposed is to leverage Immuno therapeutic "Cocktail" in conjunction with regular drugs. This would in turn help prevent the damage to blood vessels there by stemming chances of internal bleeding, firm’s Chief Scientific Officer has noted.

Unique Treatment Option

Regen BioPharma Inc. (OTCBB:RGBP) Chairman & CEO David Koos went on to provide additional information on the current thinking within the company on developing “Immunotherapeutic” approach to treat Ebola virus. He is quoted to have said that, “we believe that immunotherapeutic approaches to other areas such as Ebola may result in effective therapies as well. We are examining several forms of immunotherapy which we believe may prove beneficial in the battle against this deadly disease. At this time, we believe any such therapy may require a long period of development as Ebola is an extremely dangerous."

Treatment Methodology To Be Used For Treating Cancer and Anemia

Bio Matrix Scientific Group Inc (OTCMKTS:BMSN) has indicated that its subsidiary is also parallel working on developing in immunotherapeutic treatment procedures to treat ailments like cancer and aplastic anaemia.

Other Key Developments

Earlier this year, Bio Matrix Scientific Group Inc (OTCMKTS:BMSN) had announced that its subsidiary Regen BioPharma Inc had co-authored a research paper on the success rate of Using “Gene Silencing therapy in Heart Transplants.” The supportive data was presented for peer review in June of this year. The data showed that tests conducted on animals had demonstrated a 75% survival in HLA impacted hearts by “silencing of two genes on dendritic cells, CD40 and CD80.”

Signup now to receive the next BPS alert by clicking HERE

About BrilliantPennyStocks

BSP provides sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. BPS provides alerts to investors and traders on stocks that could potentially breakout. To obtain text message stock alerts service, text the word Avauncer to 95577 from your cell phone. Additionally, BPS provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure: BrilliantPennyStocks is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://brilliantpennystocks.com/disclaimer/ for complete risks and disclosures.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.